{{Rsnum
|rsid=1050171
|Gene=EGFR
|Chromosome=7
|position=55181370
|Orientation=plus
|GMAF=0.4183
|Gene_s=EGFR,RPL41P5
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 33.8 | 47.7 | 18.5
| HCB | 0.0 | 32.6 | 67.4
| JPT | 0.0 | 27.3 | 72.7
| YRI | 22.2 | 39.7 | 38.1
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 32.6 | 67.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=23450128
|Title=Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma
|OA=1
}}

{{PMID Auto
|PMID=17875215
|Title=Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.
|OA=1
}}

{{PMID Auto
|PMID=17956637
|Title=Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study.
|OA=1
}}

{{PMID Auto
|PMID=19563658
|Title=Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.
|OA=1
}}

{{ClinVar
|ALT=A
|CAF=0.5817; 0.4183
|CHROM=7
|CLNACC=RCV000038427.1
|CLNALLE=1
|CLNDBN=AllHighlyPenetrant
|CLNDSDB=MedGen
|CLNDSDBID=CN169374
|CLNHGVS=NC_000007.13:g.55249063G>A
|CLNSIG=2
|COMMON=1
|Disease=AllHighlyPenetrant
|FwdALT=A
|FwdREF=G
|GENEINFO=EGFR:1956; EGFR-AS1:100507500
|GENE_ID=1956; 100507500
|GENE_NAME=EGFR; EGFR-AS1
|REF=G
|RSPOS=55249063
|Reversed=0
|SAO=0
|SSR=0
|Tags=PM;TPA;PMC;SLO;VLD;G5A;G5;HD;GNO;KGPhase1;KGPilot123;KGPROD;OTHERKG;PH3;LSD
|VC=SNV
|VP=0x05017800000017051f100100
|WGT=0
|dbSNPBuildID=86
|rsid=1050171
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}